Zacks: Brokerages Anticipate Kalvista Pharmaceuticals Inc (KALV) Will Announce Earnings of -$0.45 Per Share

Wall Street brokerages expect Kalvista Pharmaceuticals Inc (NASDAQ:KALV) to announce ($0.45) earnings per share for the current quarter, according to Zacks. Three analysts have provided estimates for Kalvista Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.26). Kalvista Pharmaceuticals posted earnings of ($0.06) per share during the same quarter last year, which suggests a negative year over year growth rate of 650%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, July 30th.

On average, analysts expect that Kalvista Pharmaceuticals will report full year earnings of ($1.43) per share for the current year, with EPS estimates ranging from ($2.11) to ($1.16). For the next financial year, analysts expect that the firm will report earnings of ($2.12) per share, with EPS estimates ranging from ($4.21) to ($1.21). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative net margin of 70.08% and a negative return on equity of 19.12%. The business had revenue of $3.89 million during the quarter, compared to analyst estimates of $3.97 million.

A number of equities research analysts recently issued reports on the stock. BidaskClub raised shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, May 14th. Zacks Investment Research downgraded shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Roth Capital upped their price target on shares of Kalvista Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, May 15th. ValuEngine raised shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Needham & Company LLC assumed coverage on shares of Kalvista Pharmaceuticals in a research note on Wednesday, March 20th. They set a “buy” rating and a $35.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $30.60.

In related news, CFO Benjamin L. Palleiko sold 3,073 shares of the company’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $25.70, for a total transaction of $78,976.10. Following the sale, the chief financial officer now owns 33,573 shares of the company’s stock, valued at $862,826.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Venrock Healthcare Capital Par sold 500,000 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $28.75, for a total transaction of $14,375,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,115,719 shares of company stock worth $29,999,337. 38.40% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Flinton Capital Management LLC purchased a new stake in shares of Kalvista Pharmaceuticals in the fourth quarter valued at $26,000. Ramsey Quantitative Systems purchased a new stake in shares of Kalvista Pharmaceuticals in the fourth quarter valued at $35,000. Bank of Montreal Can purchased a new stake in shares of Kalvista Pharmaceuticals in the fourth quarter valued at $90,000. Marshall Wace North America L.P. purchased a new stake in shares of Kalvista Pharmaceuticals in the first quarter valued at $175,000. Finally, Morgan Stanley raised its stake in shares of Kalvista Pharmaceuticals by 780.7% in the first quarter. Morgan Stanley now owns 7,486 shares of the specialty pharmaceutical company’s stock valued at $214,000 after acquiring an additional 6,636 shares during the period. 77.44% of the stock is currently owned by institutional investors and hedge funds.

Kalvista Pharmaceuticals stock traded down $0.20 during mid-day trading on Friday, reaching $23.23. 500 shares of the company’s stock traded hands, compared to its average volume of 120,578. The company has a market cap of $400.30 million, a price-to-earnings ratio of -15.12 and a beta of 2.32. Kalvista Pharmaceuticals has a 12-month low of $7.73 and a 12-month high of $34.92.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Kalvista Pharmaceuticals (KALV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.